Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Vion Pharmaceuticals (United States) | Researchclopedia

Back to institutions

Vion Pharmaceuticals (United States)

New Haven, Connecticutcompany

920

Works

70,044

Citations

119

h-index

Top Research Topics

Schizophrenia research and treatment Bipolar Disorder and Treatment Epilepsy research and treatment

Top Researchers

Jun Wang Zhejiang International Studies University

3,181 works295,088 citationsh-index: 222

Recent Research

Traits, Vision, and Professionalism of Social Workers in China

Hong-Sheung Chui,Yida Yee-Ha Chung,et al.

20260 citations

Pharmacological Effects and Toxicity Studies

Pharmaceutical studies and practices

Chronic Obstructive Pulmonary Disease (COPD) Research

Attention Deficit Hyperactivity Disorder

Neuroscience and Neuropharmacology Research

Asthma and respiratory diseases

Electroconvulsive Therapy Studies

Treatment of Major Depression

Parkinson's Disease Mechanisms and Treatments

Marc Humbert Inserm

2,210 works159,210 citationsh-index: 177

Darell D. Bigner Duke University

1,127 works150,023 citationsh-index: 147

Jörge E. Cortes Augusta University Health

3,571 works143,323 citationsh-index: 179

David R. Spigel Sarah Cannon

907 works77,872 citationsh-index: 97

Howard A. Burris

1,139 works71,625 citationsh-index: 117

Le département, chef de file des politiques pour l’autonomie des personnes âgées à domicile

Alexandra Faucher,Frédéric Tallier

20260 citations

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

Lindsay Rein,Firas El Chaer,et al.

20250 citations

Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis

John Mascarenhas,Joseph M. Scandura,et al.

20251 citations

Preclinical activity of investigational menin inhibitor DSP-5336 (Enzomenib)-based combinations against MLL1-rearranged (MLL-r) or mutant-NPM1 AML models

Warren Fiskus,Christopher P. Mill,et al.

20251 citations

Monotherapy update from Phase 1 portion in Phase1/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia

Naval Daver,Joshua F. Zeidner,et al.

20253 citations